StockData
MariMed Inc. logo

MariMed Inc. (MRMD) stock

MRMDOTCMedicinal Chemicals & Botanical ProductsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 13, 2026Score 1/30
$0.06−0.00 (-3.39%)

Close on Oct 19, 2026Market cap $22.97MP/E –Yield –

Earnings

MariMed's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Nov 4, 2026
Q3 FY2026 · estimated, after the close
Revenue, Q1 FY2026
$39.50M
+4.1% on a year earlier
Adjusted EPS, Q1 FY2026
-$0.01
-$0.01 a year earlier
Latest guidance
Issued
Nov 6, 2024 · 3 items

Quarterly results

Revenue and earnings per share from each of MariMed's earnings releases, newest first

QuarterReportedRevenueYoYEPSAdj. EPSSource
Q3 FY2026ended Sep 30, 2026Nov 4, 2026Expected–––––
Q2 FY2026ended Jun 30, 2026Aug 12, 2026after the close––––Release
Q1 FY2026ended Mar 31, 2026May 13, 2026after the close$39.50M+4.1%-$0.01–Release
Q4 FY2025ended Dec 31, 2025Mar 11, 2026after the close––––Release
Q3 FY2025ended Sep 30, 2025Nov 5, 2025after the close$40.80M+0.5%-$0.01–Release
Q2 FY2025ended Jun 30, 2025Aug 6, 2025after the close––––Release
Q1 FY2025ended Mar 31, 2025May 7, 2025after the close$37.96M–-$0.01–Release
Q4 FY2024ended Dec 31, 2024Mar 5, 2025after the close––––Release
Q3 FY2024ended Sep 30, 2024Nov 6, 2024after the close$40.60M–$0.00$0.50Release
Q2 FY2024ended Jun 30, 2024Aug 7, 2024after the close––––Release
Q1 FY2024ended Mar 31, 2024May 8, 2024after the close––––Release
Q4 FY2023ended Dec 31, 2023Mar 6, 2024after the close––––Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

No open guidance: every period MariMed guided for has been reported

Guidance history

Every forecast MariMed put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Nov 6, 2024Capital ExpendituresFY2024$11.00MNew
Nov 6, 2024Non-GAAP Adjusted EBITDAFY2024-20% – -18%New
Nov 6, 2024Revenue GrowthFY2024+6% – +8%New

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases MariMed filed with the SEC as exhibits to Form 8-K or 6-K

  1. Results
  2. News
  3. News
  4. Results
  5. Results
  6. Results
  7. Results
  8. Results
  9. Results
  10. Results
  11. Results
  12. Results
  13. Results
  14. Results
  15. News

See a number that looks wrong?